A Prospective Angiotensin II versus Noradrenaline trial for Hypotension management to reduce cardiac-surgery associated Acute Kidney Injury (PAN-AKI)

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517771-21-00

Acronym

UniMs23_0019

Enrollment

1022

Registered

2025-02-06

Start date

2025-03-31

Completion date

Unknown

Last updated

2025-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury

Brief summary

Rate of AKI KDIGO stage 2 or 3 or death within 72 hours after cardiac surgery

Detailed description

MAKE90 (consisting of mortality, any dialysis within 90 days, persistent renal dysfunction (defined as > 25% eGFR reduction to baseline value at day 90), Development or progression of chronic kidney disease based on albuminuria and on two serum creatinine measurements between day 90 and 120

Interventions

DRUGGiapreza 2.5 mg/ml concentrate for solution for infusion

DRUGNOREPINEPHRINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Rate of AKI KDIGO stage 2 or 3 or death within 72 hours after cardiac surgery	—

Secondary

Measure	Time frame
MAKE90 (consisting of mortality, any dialysis within 90 days, persistent renal dysfunction (defined as > 25% eGFR reduction to baseline value at day 90), Development or progression of chronic kidney disease based on albuminuria and on two serum creatinine measurements between day 90 and 120	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026